Human Papillomavirus, Cervical Cancer, and the Vaccines

References

• Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol. 2003; 189(3 Suppl): S3–S11.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Twenty-five years of HIV/' AIDS—United States, 1981–2006. MMWR Morb Mortal Wkly Rep. 2006; 55(21): 585–589.
   PubMedGoogle Scholar
• Koutsky LA, Kiviat NB. Human papillomavirus infections. In: Holmes KK, Mardh PA, Sparling PF, et al. eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999: 347–360.
   Google Scholar
• Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 2003; 3(8): 469–475.
   PubMed Web of Science ®Google Scholar
• Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005; 32(suppl 1) S7–S15.
   PubMed Web of Science ®Google Scholar
• Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002; 109(1): 96–98.
   PubMed Web of Science ®Google Scholar
• von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001; 11(6): 598–603.
   PubMed Web of Science ®Google Scholar
• Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol. 2003; 188(3): 677–684.
   PubMed Web of Science ®Google Scholar
• Stanley M. The end for genital human papillomavirus infections? Lancet Oncol. 2005; 6(5): 256–257.
   PubMed Web of Science ®Google Scholar
• Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr. 2003; 31(3): 3–13.
   Google Scholar
• Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. IARC Sci Publ. 1992; 119: 223–241.
   Google Scholar
• American Cancer Society. Detailed Guide: Cervical Cancer. What are the key statistics about cervical cancer? Revised March 26,2008. http://www.cancer.org/docroot/CRI/content/CRI_2_4_lX_What_are_the_key_statistics_for_cervical_cancer_8.asp. Accessed May 28, 2008.
   Google Scholar
• Yabroff KR, Lawrence WF, King JC, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health. 2005; 21(2): 149–157.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37(suppl 8): S4–S66.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2): 153–156.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Cancer Statistics Review. Estimated new cancer cases and deaths for 2005. http://seer.cancer.gov/csr/1975_2002/results_single/sect_0l_table.01.pdf. Accessed May 28, 2008.
   Google Scholar
• Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157(3): 218–226.
   PubMed Web of Science ®Google Scholar
• Naud P, Matos J, Hammes L, et al. Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil. Eur J Obstet Gynecol Reprod Biol. 2006; 124(1): 110–118.
   PubMed Web of Science ®Google Scholar
• Gunnell AS, Tran TN, Torrang A, et al. Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development. Cancer Epidemiol Biomarkers Prev. 2006; 15(11): 2141–2147.
   PubMed Web of Science ®Google Scholar
• Chuang TY. Condylomata acuminata (genital warts). An epidemiologic view. J Am Acad Dermatol. 1987; 16(2 pt 1): 376–384.
   PubMed Web of Science ®Google Scholar
• Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Incidence and clinical picture. Acta Obstet Gynecol Scand. 1996; 75(3): 287–290.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. US Department of Health and Human Services. Sexually transmitted disease surveillance, 2006. http://www.cdc.gov/std/stats/tables/table42.htm. Published November 13, 2007. Accessed May 28, 2008.
   Google Scholar
• Ault KA. Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine. Obstet Gynecol Clin North Am. 2003; 30(4): 809–817.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Trends in sexual risk behaviors among high school students—United States, 1991–2001. MMWR Morb Mortal Wkly Rep. 2002; 51(38): 856–859.
   PubMedGoogle Scholar
• Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis. 2002; 29(11): 725–735.
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006; 354(25): 2645–2654.
   PubMed Web of Science ®Google Scholar
• Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002; 35(suppl 2): S210–S224.
   PubMedGoogle Scholar
• Gardasil [package insert]. Merck and Co., Inc. Whitehouse Station, NJ; 2008. https://www.merckvaccines.com/gardasilProductPage_fhnst.html. Accessed May 28, 2008.
   Google Scholar
• Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 LI virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11): 1459–1466.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) LI virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5): 271–278.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, et al; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347(21): 1645–1651.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, et al; GlaxoSmithKline HPV Vaccination Study Group. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364(9447): 1757–1765.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19): 1915–1927.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19): 1928–1943.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiva M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practice (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2): 1–24.
   PubMedGoogle Scholar
• American College of Obstetricians and Gynecologists ACOG). (HPV vaccine-ACOG recommendations. August 2006. http://www.acog.org/departments/dept_notice.cfm?recno=7&bulletin=3945. Accessed May 12, 2008.
   Google Scholar
• Centers for Disease Control and Prevention. Syncope after vaccination- United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17): 457–60.
   PubMedGoogle Scholar